Comparative lytic efficacy of rt-PA and ultrasound in porcine versus human clots

Microscopy Microbubbles Swine Science Q R Contrast Media Thrombosis In Vitro Techniques Time-Lapse Imaging Recombinant Proteins 3. Good health Plasma 03 medical and health sciences 0302 clinical medicine Species Specificity Tissue Plasminogen Activator Medicine Animals Humans Research Article Ultrasonography
DOI: 10.1371/journal.pone.0177786 Publication Date: 2017-05-18T19:00:46Z
ABSTRACT
Porcine thrombi are employed routinely in preclinical models of ischemic stroke. In this study, we examined the differential lytic susceptibility of porcine and human whole blood clots with and without the use of microbubbles and ultrasound (US) as an adjuvant.An in vitro system equipped with time-lapse microscopy was used to evaluate recombinant tissue-plasminogen activator (rt-PA) lysis of porcine and human clots in the same species or cross species plasma. Human and porcine whole blood clots were treated with rt-PA and an echo contrast agent, Definity®, and exposed to intermittent 120 kHz US.The rt-PA lytic efficacy observed for porcine clots in porcine plasma was 22 times lower than for human clots in human plasma reported previously. Further, porcine clots did not exhibit increased lysis with adjuvant Definity® and US exposure. However, the rt-PA lytic susceptibility of the porcine clots in human plasma was similar to that of human clots in human plasma. Human clots perfused with porcine plasma did not respond to rt-PA, but adjuvant use of Definity® and US enhanced lysis. These results reveal considerable differences in lytic susceptibility of porcine clots and human clots to rt-PA. The use of porcine clot models to test new human thrombolytic therapies may necessitate modulation of coagulation and thrombolytic factors to reflect human hemostasis accurately.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (68)
CITATIONS (5)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....